Drug intelligence / Profile preview

SY-12882

Development stage: Preclinical
Lead developer: Syros Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SY-12882 is an oral, potent, and selective small molecule inhibitor of cyclin-dependent kinase 12 (CDK12), developed by Syros Pharmaceuticals. It is designed to modulate gene expression by inhibiting CDK12, a kinase involved in transcriptional regulation and DNA damage response. The drug is being investigated primarily for oncology indications, with preclinical studies focusing on its antineoplastic potential. As of the latest updates, SY-12882 remains in preclinical development and has not yet entered clinical trials[1][4][5][9].

Targets

CDK12

Beyond the preview

Go deeper on SY-12882.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-12882.

Explore the full profile